Monday, October 5, 2026

OpenAI raises $110B at $840B valuation as AI infrastructure attracts record early-stage capital

OpenAI secured $110B at an $840B valuation while Anthropic raised $30B at $380B, anchoring a sharp acceleration in early 2026 venture capital. Investor appetite extends beyond foundation models to robotics automation, healthcare AI, and climate tech, with funding distributed from seed through Series C stages.

LM Salvado

March 16, 2026

OpenAI raises $110B at $840B valuation as AI infrastructure attracts record early-stage capital
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

OpenAI closed a $110B funding round at an $840B valuation in early 2026, marking the largest capital raise in AI foundation model history. Anthropic followed with a $30B round at a $380B valuation, cementing investor confidence in core AI infrastructure.

The mega-rounds anchor a broader surge in venture capital deployment across AI-adjacent sectors. Robotics automation, healthcare AI applications, and climate technology startups attracted substantial seed through Series C funding, signaling diversification beyond pure foundation model plays.

Late-stage thesis-driven firms led the OpenAI and Anthropic rounds, while specialized sector funds deployed capital into applied automation technologies. This dual approach reflects investor conviction that AI infrastructure will support vertical-specific applications across industries.

Robotics companies building warehouse automation and manufacturing systems secured multiple Series A and B rounds. Healthcare AI startups focused on diagnostic automation and clinical workflow tools attracted early-stage capital from both generalist and healthcare-focused funds.

Climate tech emerged as another beneficiary, with investors backing startups applying AI to energy optimization, carbon tracking, and supply chain efficiency. Vertical SaaS platforms integrating AI capabilities also captured investor attention, particularly in sectors lagging technology adoption.

The funding environment marks a shift from 2024-2025, when capital concentrated almost exclusively in foundation model developers. Early 2026 data shows capital spreading to companies building on top of or alongside base models, reducing dependence on a small number of infrastructure providers.

Investor appetite spans risk profiles, with seed-stage checks flowing to unproven robotics concepts alongside late-stage billion-dollar bets on established AI labs. This distribution suggests confidence extends beyond near-term foundation model dominance to longer-term automation deployment across physical and digital workflows.

The funding surge positions 2026 as a potential inflection point for AI commercialization beyond chatbots and code assistants, with robotics and specialized enterprise tools entering production at scale.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score3 source documents3 with a live linkVerifiability: Strong
  1. [1]News articleCrunchbase News
    5 Interesting Startup Deals You May Have Missed: Blood-Drawing Robots, Inboxes For AI Agents, Franchised Defense Manufacturing, And More
  2. [2]Press releaseGlobeNewswire· March 10, 2026
    Moxie Raises $25M Series C to Bring Clinical-Grade Operating Infrastructure to Independent Aesthetic Practices
  3. [3]News articleCrunchbase News
    While OpenAI Shattered Records, Robotics and Semiconductor Startups Quietly Added The Most New Unicorns In February

In this story

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com